Abstract
Among viral and non-viral gene delivery systems, SV40-based vectors show great promise in the cancer gene therapy field. SV40 vectors very efficiently deliver genes such as anti-viral agents, DNA vaccine, genes for chemoprotection (such as ABC transporters genes), suicide genes and antiangiogenic genes. The recombinant SV40 vectors can infect a wide variety of cells-dividing cells as well as non-cycling ones. Most of the SV40-based vectors can incorporate larger transgenes than the capacity of the SV40 wild-type, which is 5.2 kb; Moreover, in vitro packaged vectors demonstrate efficient delivery of plasmids with a molecular weight of up to 17.7 kb. SV40-based vectors carry some SV40 viral sequences, but the SV40 in vitro-packaged vectors are free of any SV40 wild-type viral DNA sequences. These vectors are prepared with nuclear extracts of SF9 insect cells containing the main viral capsid protein of the SV40 wild-type virus, VP1. This review summarizes different strategies in which SV40 vectors are used to deliver genes in vitro, to living mice, and to tumors growing in nude mice.
Keywords: sv40 vectors, sv40 in vitro packaging, high efficiency, chemoprotection, anti-hiv gene therapy, pseudomonas exotoxin, pigment epithelium derived factor
Current Pharmaceutical Biotechnology
Title: SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer and their Potential Application in Cancer Therapy
Volume: 5 Issue: 5
Author(s): Chava Kimchi-Sarfaty and Michael M. Gottesman
Affiliation:
Keywords: sv40 vectors, sv40 in vitro packaging, high efficiency, chemoprotection, anti-hiv gene therapy, pseudomonas exotoxin, pigment epithelium derived factor
Abstract: Among viral and non-viral gene delivery systems, SV40-based vectors show great promise in the cancer gene therapy field. SV40 vectors very efficiently deliver genes such as anti-viral agents, DNA vaccine, genes for chemoprotection (such as ABC transporters genes), suicide genes and antiangiogenic genes. The recombinant SV40 vectors can infect a wide variety of cells-dividing cells as well as non-cycling ones. Most of the SV40-based vectors can incorporate larger transgenes than the capacity of the SV40 wild-type, which is 5.2 kb; Moreover, in vitro packaged vectors demonstrate efficient delivery of plasmids with a molecular weight of up to 17.7 kb. SV40-based vectors carry some SV40 viral sequences, but the SV40 in vitro-packaged vectors are free of any SV40 wild-type viral DNA sequences. These vectors are prepared with nuclear extracts of SF9 insect cells containing the main viral capsid protein of the SV40 wild-type virus, VP1. This review summarizes different strategies in which SV40 vectors are used to deliver genes in vitro, to living mice, and to tumors growing in nude mice.
Export Options
About this article
Cite this article as:
Kimchi-Sarfaty Chava and Gottesman M. Michael, SV40 Pseudovirions as Highly Efficient Vectors for Gene Transfer and their Potential Application in Cancer Therapy, Current Pharmaceutical Biotechnology 2004; 5 (5) . https://dx.doi.org/10.2174/1389201043376670
DOI https://dx.doi.org/10.2174/1389201043376670 |
Print ISSN 1389-2010 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4316 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Cancer Antibody Enhanced Real Time Imaging Cell Probes – a Novel Theranostic Tool using Polymer Linked Carbon Nanotubes and Quantum Dots
Anti-Cancer Agents in Medicinal Chemistry PDE5 Inhibitors Offer Novel Mechanisms in Combination and Solo Cancer Therapy
Current Cancer Therapy Reviews Regulation of Microtubule: Current Concepts and Relevance to Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Curcumin: Structure-Activity Relationship Towards its Role as a Versatile Multi-Targeted Therapeutics
Mini-Reviews in Organic Chemistry Toxicological Aspects of Carbon Nanotubes, Fullerenes and Graphenes
Current Pharmaceutical Design The Impact of Inflammatory Bowel Disease (IBD) and its Treatment on the Reproductive Process
Current Women`s Health Reviews Plant Glutathione Transferases: Structure, Antioxidant Catalytic Function and in planta Protective Role in Biotic and Abiotic Stress
Current Chemical Biology Monoamine Oxidase Inhibitors: Ten Years of Docking Studies
Current Topics in Medicinal Chemistry Inhibition of NADPH: Quinone Oxidoreductase Activity of Camel Lens ζ-Crystallin by Colchicine
Current Enzyme Inhibition Ligands and Therapeutic Perspectives of Adenosine A2A Receptors
Current Pharmaceutical Design The Advance of Dendrimers - A Versatile Targeting Platform for Gene/Drug Delivery
Current Pharmaceutical Design Development and Tailoring of Hybrid Lipid Nanocarriers
Current Pharmaceutical Design Endogenous Retroelements in Cellular Senescence and Related Pathogenic Processes: Promising Drug Targets in Age-Related Diseases
Current Drug Targets Purine Molecules as Hypnogenic Factors Role of Adenosine, ATP, and Caffeine
Central Nervous System Agents in Medicinal Chemistry Resistance of Cancer Cells to Targeted Therapies Through the Activation of Compensating Signaling Loops
Current Signal Transduction Therapy Current Treatment Options for HCC: From Pharmacokinetics to Efficacy and Adverse Events in Liver Cirrhosis
Current Drug Metabolism Staphylococcus aureus: The Toxic Presence of a Pathogen Extraordinaire
Current Medicinal Chemistry Procarbazine – A Traditional Drug in the Treatment of Malignant Gliomas
Current Medicinal Chemistry Self Emulsifying Drug Delivery System (SEDDS) for Phytoconstituents: A Review
Current Drug Delivery Recent Studies on Macromolecular Synthesis Labeled with 3H-Thymidine in Various Organs as Revealed by Electron Microscopic Radioautography
Current Radiopharmaceuticals